Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase.
Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, USA.
S V
SV
Frye
H N
HN
Bramson
D J
DJ
Hermann
F W
FW
Lee
A K
AK
Sinhababu
G
G
Tian
D000818:Animals; D001378:Azasteroids / Q000493:pharmacokinetics / Q000494:pharmacology*; D042944:Cholestenone 5 alpha-Reductase; D013196:Dihydrotestosterone / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D018120:Finasteride / Q000494:pharmacology; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors* / Q000502:physiology
D001378:Azasteroids; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D013196:Dihydrotestosterone; D018120:Finasteride; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase; D000068538:Dutasteride